Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Actuate Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ACTU
Nasdaq
2834
actuatetherapeutics.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Actuate Therapeutics, Inc.
Actuate Therapeutics Reports Positive Monotherapy Data in Aggressive Melanoma Preclinical Model with Daily Dosing of Elraglusib Oral Tablet at ENA 2026
- Nov 18th, 2026 6:00 am
Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026
- Nov 4th, 2026 6:00 am
Actuate Therapeutics Receives U.S. Notice of Allowance for Patent Covering Elraglusib Oral Tablets
- Nov 2nd, 2026 6:00 am
Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering
- Oct 27th, 2026 6:00 am
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia
- Oct 12th, 2026 9:07 am
AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer
- Oct 8th, 2026 8:47 am
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Sep 9th, 2026 3:00 pm
Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib
- Sep 9th, 2026 5:00 am
Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
- Jun 9th, 2026 5:45 am
Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
- Jun 1st, 2026 5:00 am
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
- May 11th, 2026 5:00 am
Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
- May 6th, 2026 6:45 am
Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
- Apr 14th, 2026 6:45 am
Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers
- Mar 24th, 2026 5:00 am
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
- Mar 9th, 2026 6:45 am
Actuate Therapeutics to Present at The Citizens Life Sciences Conference
- Mar 4th, 2026 3:00 pm
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Feb 24th, 2026 6:45 am
Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) market cap dropped US$13m last week; Private equity firms bore the brunt
- Feb 4th, 2026 5:06 am
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
- Jan 21st, 2026 6:45 am
Scroll